A novel fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report
Anaplastic lymphoma kinase ( ALK ) rearrangement occurs in approximately 5% of non-small cell lung cancers (NSCLCS), and EML4-ALK is the most commonly observed ALK fusion variant in NSCLC. However, growth hormone receptor ( GHR ) as the fusion partner for ALK and the clinical response to ALK tyrosin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-09-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605211044652 |